$16.83 Million in Sales Expected for Melinta Therapeutics Inc (MLNT) This Quarter

Equities research analysts expect Melinta Therapeutics Inc (NASDAQ:MLNT) to announce $16.83 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Melinta Therapeutics’ earnings, with the lowest sales estimate coming in at $15.45 million and the highest estimate coming in at $18.20 million. Melinta Therapeutics posted sales of $14.84 million in the same quarter last year, which suggests a positive year over year growth rate of 13.4%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Melinta Therapeutics will report full-year sales of $80.15 million for the current fiscal year, with estimates ranging from $66.01 million to $101.59 million. For the next financial year, analysts anticipate that the business will report sales of $110.08 million, with estimates ranging from $98.00 million to $143.32 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that cover Melinta Therapeutics.

Several research firms have recently commented on MLNT. Zacks Investment Research downgraded shares of Melinta Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. ValuEngine downgraded shares of Melinta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 1st. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $55.00.

MLNT traded up $0.11 during trading on Friday, hitting $3.55. The stock had a trading volume of 204,900 shares, compared to its average volume of 416,621. The company has a market cap of $38.72 million, a price-to-earnings ratio of -0.20 and a beta of 2.28. Melinta Therapeutics has a twelve month low of $3.20 and a twelve month high of $46.00. The company has a quick ratio of 0.81, a current ratio of 1.12 and a debt-to-equity ratio of 0.58.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace North America L.P. acquired a new position in Melinta Therapeutics during the third quarter valued at $48,000. Rhumbline Advisers lifted its position in Melinta Therapeutics by 59.1% during the fourth quarter. Rhumbline Advisers now owns 44,129 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 16,400 shares during the period. Condor Capital Management acquired a new position in Melinta Therapeutics during the fourth quarter valued at $55,000. TIAA CREF Investment Management LLC lifted its position in Melinta Therapeutics by 23.7% during the third quarter. TIAA CREF Investment Management LLC now owns 90,646 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 17,360 shares during the period. Finally, ClariVest Asset Management LLC lifted its position in Melinta Therapeutics by 50.0% during the third quarter. ClariVest Asset Management LLC now owns 97,200 shares of the biotechnology company’s stock valued at $384,000 after purchasing an additional 32,400 shares during the period.

Melinta Therapeutics Company Profile

Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.

Read More: Dollar Cost Averaging

Get a free copy of the Zacks research report on Melinta Therapeutics (MLNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Melinta Therapeutics (NASDAQ:MLNT)

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.